Arthur Groy

1.7k total citations
7 papers, 696 citations indexed

About

Arthur Groy is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Neurology. According to data from OpenAlex, Arthur Groy has authored 7 papers receiving a total of 696 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 4 papers in Endocrinology, Diabetes and Metabolism and 2 papers in Neurology. Recurrent topics in Arthur Groy's work include Growth Hormone and Insulin-like Growth Factors (4 papers), Neuroblastoma Research and Treatments (2 papers) and Metabolism, Diabetes, and Cancer (2 papers). Arthur Groy is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (4 papers), Neuroblastoma Research and Treatments (2 papers) and Metabolism, Diabetes, and Cancer (2 papers). Arthur Groy collaborates with scholars based in United States, Netherlands and Canada. Arthur Groy's co-authors include Jingsong Yang, Roland S. Annan, Kelly E. Fisher, Francesca Zappacosta, Aidan G. Gilmartin, Swarupa G. Kulkarni, Sylvie Laquerre, David Sutton, Symon G. Erskine and Maureen R. Bleam and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and Molecular Cancer Therapeutics.

In The Last Decade

Arthur Groy

7 papers receiving 675 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Arthur Groy United States	6	497	279	122	109	81	7	696
Kelly E. Fisher United States	4	434 0.9×	288 1.0×	76 0.6×	91 0.8×	87 1.1×	6	599
Eli Wallace United States	9	538 1.1×	296 1.1×	106 0.9×	111 1.0×	53 0.7×	16	697
Yogindra Persaud United States	6	619 1.2×	368 1.3×	151 1.2×	136 1.2×	105 1.3×	12	818
Nyam Kamsu-Kom France	10	662 1.3×	615 2.2×	117 1.0×	84 0.8×	64 0.8×	12	1.0k
Marian M. Deuker United States	6	580 1.2×	274 1.0×	65 0.5×	118 1.1×	117 1.4×	6	742
T. Ahmad United Kingdom	7	566 1.1×	388 1.4×	66 0.5×	78 0.7×	82 1.0×	12	677
Zoi Karoulia United States	6	560 1.1×	238 0.9×	85 0.7×	130 1.2×	115 1.4×	9	664
Joe Lyssikatos United States	6	380 0.8×	207 0.7×	80 0.7×	87 0.8×	42 0.5×	8	502
Katie Kane United Kingdom	6	363 0.7×	256 0.9×	101 0.8×	77 0.7×	50 0.6×	9	531
Amy Weise United States	19	438 0.9×	530 1.9×	259 2.1×	83 0.8×	30 0.4×	69	946

Countries citing papers authored by Arthur Groy

Since Specialization

Citations

This map shows the geographic impact of Arthur Groy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arthur Groy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arthur Groy more than expected).

Fields of papers citing papers by Arthur Groy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arthur Groy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arthur Groy. The network helps show where Arthur Groy may publish in the future.

Co-authorship network of co-authors of Arthur Groy

This figure shows the co-authorship network connecting the top 25 collaborators of Arthur Groy. A scholar is included among the top collaborators of Arthur Groy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arthur Groy. Arthur Groy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

Béliveau, François, Sébastien P. Dion, Antoine Désilets, et al.. (2019). Discovery and Development of TMPRSS6 Inhibitors Modulating Hepcidin Levels in Human Hepatocytes. Cell chemical biology. 26(11). 1559–1572.e9. 25 indexed citations

Ott, Heidi M., Alan P. Graves, Melissa B. Pappalardi, et al.. (2014). A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation. Molecular Cancer Therapeutics. 13(12). 3062–3073. 35 indexed citations

Gilmartin, Aidan G., Maureen R. Bleam, Arthur Groy, et al.. (2011). GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition. Clinical Cancer Research. 17(5). 989–1000. 459 indexed citations

Sabbatini, Peter, Susan Korenchuk, Jason L. Rowand, et al.. (2009). GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Molecular Cancer Therapeutics. 8(10). 2811–2820. 86 indexed citations

Sabbatini, Peter, Jason L. Rowand, Arthur Groy, et al.. (2009). Antitumor Activity of GSK1904529A, a Small-molecule Inhibitor of the Insulin-like Growth Factor-I Receptor Tyrosine Kinase. Clinical Cancer Research. 15(9). 3058–3067. 62 indexed citations

Rabindran, Sridhar K., Peter Sabbatini, Susan Korenchuk, et al.. (2009). Abstract #1740: Characterization of GSK1838705A, a small molecule inhibitor of the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase that delays growth of IGF-1R-dependent tumors and causes regression of ALK-dependent tumors in vivo. Cancer Research. 69. 1740–1740. 2 indexed citations

Chamberlain, Stanley D., Joseph W. Wilson, Felix Deanda, et al.. (2008). Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: Potent inhibitors of the IGF-1R receptor tyrosine kinase. Bioorganic & Medicinal Chemistry Letters. 19(2). 469–473. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact